Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company’s product pipeline also includes IFX-2, which is in preclinical development.
Market Cap:113M; Shares Outstanding:26.1M; Q3 2019(9/30/19): Cash 62.23M. Loss year 33.5M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 631，no change
Shares hold: 4539.7k shares. no change
shares% hold: 17.48%，no change